Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Barritt D.W., Jordan S.C..
Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial.
Lancet, 1 (1960), pp. 1309-1312
[2.]
Becker R.C., Berkowitz S.D..
Hemostatic aspects of cardiovascular medicine.
Consultative hemostasis and thrombosis, pp. 279-310
[3.]
Boccalon H., Elias A., Chale J.J., Cadene A., Gabriel S..
Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study.
Arch Intern Med., 160 (2000), pp. 1769-1773
[4.]
Boccalon H., Elias A., Chale J.J., Cadene A., Dumoulin A..
Treatment of deep venous thrombosis at home: evolution from ideas to medical practice.
Bull Acad Natl Med., 182 (1998), pp. 101-115
[5.]
Boneu B..
Low molecular weight heparins Are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis.
Thromb Research, 100 (2000), pp. 113-120
[6.]
Borrellas X., Monasterio J., Piera L.L., et al.
Heparinas de bajo peso molecular en la insuficiencia renal.
Heparinas de bajo peso molecular, pp. 159-167
[7.]
Brandjes D.P., Heijboer H., Buller H.R., De Rijk M., Jagt H., Ten Cate J.W..
Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
N Engl J Med., 327 (1992), pp. 1485-1489
[8.]
Briggs A.H., O'Brien B.J..
The death of cost-minimization analysis?.
Health Econ, 10 (2001), pp. 179-184
[9.]
Casals FJ. Trombosis venosa. Barcelona: Masson. 107-38.
[10.]
Cockroft D.W., Gault M.N..
Prediction of creatinin clearence from serum creatinin.
Nephron, 16 (1976), pp. 31-41
[11.]
Conner C. et al. Innohep User's meeting. Windsor; 1999.
[12.]
Couturaud F., Julian J.A., Kearon K..
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism.
Thromb Haemost, 86 (2001), pp. 980-984
[13.]
Charbonnier B.A., Fiessinger J.N., Banga J.D., Wenzel E., D'Azemar P., Sagnard L..
Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
Thromb Haemost, 79 (1998), pp. 897-901
[14.]
Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., Cheah G..
A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism.
Arch Int Med., 160 (2000), pp. 181-188
[15.]
DUTENOX Study Group.
Markers of hemostatic system activation in acute deep vein thrombosis evolution during the first days of heparin treatment.
Thromb Haemost, 70 (1993), pp. 909-914
[16.]
Fiessinger H. Thrombose au quotidien. 2001.
[17.]
Fiessinger J.N., López-Fernández N., Gatterer E., Granqvist S., Kher A., Olsson C.G., et al.
Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
Thromb Haemost, 76 (1996), pp. 195-199
[18.]
Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., Garber A.M..
Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized controlled trials.
Ann Intern Med., 130 (1999), pp. 800-809
[19.]
Gould M.K., Dembitzer A.D., Sanders G., Garber A.M..
Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A cost effectiveness analysis.
Ann Intern Med., 130 (1999), pp. 789-799
[20.]
Grau E., Real E., Pastor E., Viciano V., Aguiló J..
Home treatment of deep vein thrombosis: a two-years experience of a single institution.
Haematologica, 83 (1998), pp. 438-441
[21.]
Grau E., Tenias J.M., Real E., Medrano J., Ferrer R., Pastor E., et al.
Home treatment of deep venous thrombosis with low molecular weight heparin: long-term incidence of recurrent venous thromboembolism.
Am J Hematol, 67 (2001), pp. 10-14
[22.]
Griffin J..
Deep vein thrombosis and pulmonary embolism, Office of Health Economics, (1996),
[23.]
Groce J.B..
Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program.
Pharmacotherapy, 6 (1998), pp. S18
[24.]
Harrison L., McGinnis J., Crowther M., Ginsberg J., Hirsh J..
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin.
Arch Intern Med., 158 (1998), pp. 2001-2003
[25.]
Hirsh J., Lee A.Y.Y..
How we diagnose and treat deep vein thrombosis.
Blood, 99 (2002), pp. 3102-3110
[26.]
Holst J., Lindblatd B., Bergqvist D., Garre K., Nielsen H., Hedner U., et al.
Protamine neutralization of intravenous and subcutaneous low molecular weight heparin (tinzaparin, logiparin). An experimental investigation in healhty volunteers.
Blood Coagul Fibrinolysis, 5 (1994), pp. 795-803
[27.]
Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G., et al.
Subcutaneous low molecular weight heparin compared with continous intravenous heparin in the treatment of proximal deep vein thrombosis.
N Engl J Med., 326 (1992), pp. 975-982
[28.]
Huse D.M., Cummins G., Taylor D.C., Russell M.W..
Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Am J Manag Care, 8 (2002), pp. S10-S16
[29.]
Hyers T.M., Agnelli G., Hull R.D., Morris T.A., Samama M., Tapson V., et al.
Antithrombotic therapy for venous thromboembolic disease.
Chest, 119 (2001), pp. S176-S193
[30.]
Kakkar V.V., Gebska M., Kadziola Z., et al.
Objective assesment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis, XVIII Congress International Society Thrombosis and Haemostasis, (2001),
[31.]
Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., Van der Meer J., et al.
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
N Engl J Med., 334 (1996), pp. 682-687
[32.]
Kovacs M.J., Anderson D., Morrow B., Gray L., Touchie D., Wells P.S..
Outpatient treatment of pulmonary embolism with dalteparin.
Thromb Haemost, 83 (2000), pp. 209-211
[33.]
Laurent P., Dussarat G.V., Bonal J., Jego C., Talard P., Bouchiat C., et al.
Low molecular weight heparins. A guide to their optimum use in pregnancy.
Drugs, 62 (2002), pp. 463-477
[34.]
Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J., et al.
A comparison of low-molecular-weight heparin administred primarily at home with unfractinated heparin administred in the hospital for proximal deep-vein-thrombosis.
N Engl J Med., 334 (1996), pp. 677-682
[35.]
Leizorovicz A., Simonneau G., Decousus H., Boissel J.P..
Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta analysis.
BMJ, 309 (1994), pp. 299-304
[36.]
Lensing A.W.A., Prins M., Davidson B.L., Hirsh J..
Treatment of deep venous thrombosis with low molecular weight heparins. A meta analysis.
Arch Intern Med., 155 (1995), pp. 601-607
[37.]
Lindmarker P..
Use of low-molecular-weight heparin (dalteaorin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. Swedish venous thrombosis Dalteparin Trial Group.
J Intern Med., 240 (1996), pp. 395-401
[38.]
Lindmarker P..
Can all patients with deep vein thrombosis receive own molecular weight heparin in an outpatient setting?.
Haemostasis, 29 (1999), pp. 84-88
[39.]
Miles J. et al. Presentation to American Thoracic Society; 1998
[40.]
Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al.
Subcutaneous enoxiparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Ann Int Med., 134 (2001), pp. 191-202
[41.]
O'Brien B., Levine M., Willan A., Goeree R., Haley S., Blackhouse G., et al.
Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
Arch Intern Med., 159 (1999), pp. 2298-2304
[42.]
O'Shaugnessy D.F., et al.
Outpatient management of deep vein thrombosis.
J Acc Emerg Med., 15 (1998), pp. 292-293
[43.]
Pacouret G., Alison D., Pottier J.M., Bertrand P., Charbonnier B..
Free floating thrombus and embolic risk in patients with angiographically confirmed deep vein thrombosis. A prospective study.
Arch Int Med., 157 (1997), pp. 305-308
[44.]
Palareti G., Legnani C., Lee A., Manotti C., Hirsh J., D'Angelo A., et al.
A comparison of the safety and efficacy of oral anticoagulants for the treatment of venous thromboembolic disease in patients with or without malignancy.
Thromb Haemost, 84 (2000), pp. 805-810
[45.]
Partsch H., Kechavarz B., Mostbeck A., Kohn H., Lipp C..
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once-or twice daily low molecular weight heparin.
J Vasc Surg., 24 (1996), pp. 774-782
[46.]
Rocha E., Martínez-González M.A., Montes R., Panizo C..
Do the low molecular wight heparins improve efficacy and safety of the treatment of deep venous thrombosis?.
A meta-analysis. Haematologica, 85 (2000), pp. 935-942
[47.]
Rodger M., Bredeson C., Wells P.S., Beck J., Kearns B., Huebsch L.B..
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
CMAJ, 159 (1998), pp. 931-938
[48.]
Schraibman IG, Milne AA, Royle EM. Home versus in-patient treatment for deep vein thrombosis. Cochrane review. Cochrane Library Issue 2; 2002.
[49.]
The Columbus Investigators.
Low molecular weight heparin in the treatment of patients with venous thromboembolism.
N Engl J Med., 337 (1997), pp. 657-662
[50.]
Ting S.B., Ziegenbein R.W., Gan T.E., Catalano J.V., Monagle P., Silvers J., et al.
Dalteparin for deep venous thrombosis: a hospital-in-the-home program.
Med J Aust, 168 (1998), pp. 272-276
[51.]
Turpie A.G.G..
Looking forward in the treatment of deep-vein thrombosis.
Semin Hematol, 38 (2001), pp. 49-57
[52.]
Van den Belt A.G., Bossuyt P.M., Prins M.H., Gallus A.S., Buller H.R..
Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis –an economic evaluation. TASMAN Study Group.
Thromb Haemost, 79 (1998), pp. 259-263
[53.]
Van den Belt AG, et al. Oxford: The Cochrane Library; 1999.
[54.]
Van der Heijden J.F., Prins M., Buller H.R..
For the initial treatment of venous thromboembolism: are low molecular weight heparin compounds the same?.
Thromb Res., 100 (2000), pp. 121-130
[55.]
Van der Heijden J.F., Prins M., Buller H.R..
Low molecular weight heparins: are they interchangeable?.
Haemostasis, 30 (2000), pp. 148-157
[56.]
Wells P.S., Anderson D.R., Bormanis J., Guy F., Mitchell M., Gray L., et al.
Value of assessment of pretest probability of deep-vein thrombosis in clinical management.
Lancet, 350 (1997), pp. 1795-1798
[57.]
Wells P.S., Kovacs M.J., Bormanis J., Forgie M.A., Goudie D., Morrow B., et al.
Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.
Arch Int Med., 158 (1998), pp. 1809-1812
[58.]
Wells P.S..
Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism.
Curr Opn Pulm Med., 7 (2001), pp. 360-364
[59.]
Wimperis J.Z., et al.
Br J Haematol, (1998), pp. 101
[60.]
Warkentin T.E., Levine M.N., Hirsh J., et al.
Formation of heparin induced thrombocytopenia IgG without thrombocytopenia: analysis of clinical trial.
Blood, 86 (1995), pp. 537
[61.]
Yurkowski P..
Issues in developing an outpatient deep venous thrombosis treatment program: university hospital experience.
Pharmacotherapy, 18 (1998), pp. S165-S169
Copyright © 2003. SEACV
